Literature DB >> 3000581

Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors.

Y Pommier, R E Schwartz, L A Zwelling, D Kerrigan, M R Mattern, J Y Charcosset, A Jacquemin-Sablon, K W Kohn.   

Abstract

DNA intercalating drugs and the epipodophyllotoxins etoposide and teniposide interfere with the action of mammalian DNA topoisomerase II by trapping an intermediate complex of the enzyme covalently linked to the 5'-termini of DNA breaks. This effect can be observed in intact cells by alkaline elution measurement of protein-associated DNA strand breaks. To assess the cytotoxic role of this effect, we have studied a subline of DC3F Chinese hamster lung cells selected for resistance to the intercalating agent 9-hydroxyellipticine. This subline (DC3F/9-OHE) was cross-resistant to other intercalators as well as to etoposide. Resistance to Adriamycin was associated with reduced uptake. However, resistance to 4'-(9-acridinylamino)methanesulfon-m-aniside and 2-methyl-9-hydroxyellipticinium was observed in the absence of changes in drug uptake, suggesting a second mode of resistance. DC3F/9-OHE cells formed fewer protein-associated DNA strand breaks in response to 4'-(9-acridinylamino)methanesulfon-m-aniside, 2-methyl-9-hydroxyellipticinium, or etoposide than did the sensitive parental cells. The same was true for isolated nuclei from these cells, which is consistent with a mode of resistance unrelated to drug uptake through the plasma membrane. These data suggest that resistance to DNA topoisomerase II inhibitors exhibited by DC3F/9-OHE cells is due in part to a modification of topoisomerase II activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3000581

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids.

Authors:  B S Glisson; A M Killary; P Merta; W E Ross; J Siciliano; M J Siciliano
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Etoposide-induced DNA cleavage in human leukemia cells.

Authors:  C M Edwards; B S Glisson; C K King; S Smallwood-Kentro; W E Ross
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 3.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Association of sorcin with drug resistance in L1210 cells.

Authors:  D Roberts; M B Meyers; J L Biedler; L G Wiggins
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 5.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

6.  Digital cell image analysis of verapamil-induced effects in chemosensitive and chemoresistant neoplastic cell lines.

Authors:  C Etiévant; O Pauwels; R Kiss
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine.

Authors:  C M Chresta; R Hicks; J A Hartley; R L Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Antitumor activity of new anthracycline analogues in combination with interferon alfa.

Authors:  M E Berens; T Saito; C E Welander; E J Modest
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Effects of the antitumor drug VP16 (etoposide) on the archaebacterial Halobacterium GRB 1.7 kb plasmid in vivo.

Authors:  M Sioud; P Forterre; A M de Recondo
Journal:  Nucleic Acids Res       Date:  1987-10-26       Impact factor: 16.971

10.  Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.

Authors:  B Y Bugg; M K Danks; W T Beck; D P Suttle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.